Final frontier for meds? UK startup sends drug-making into space
THE SO WHAT
Drug discovery is following semiconductors into extreme environments — BioOrbit is betting ISS-grown ultra-pure protein crystals can unlock self-injected cancer treatments at scale. If you’re in biotech, your competitive set now includes orbital manufacturing plays, not just better wet labs on Earth.
READ THE SOURCE
MORE FROM THE WIRE
Deep & Emerging TechIntel’s Arc G3 is the handheld chip we needed, at the worst possible time
A credible Intel handheld GPU four years after the Steam Deck shows how fast timing can erase technical wins — platform and ecosystem already consolidated around AMD. If you’re building hardware-dependent products, your real risk isn’t spec parity, it’s missing the adoption window where devs and modders pick their default stack.
Deep & Emerging TechPolymarket blocks VPNs and tightens identity verification as over 30 countries ban the betting platform
When a prediction market starts blocking VPNs and tightening KYC after 30+ country bans, the era of truly permissionless retail prediction is closing. If your product touches regulated behavior — money, health, elections — assume geo-fencing, identity, and compliance will become core engineering problems, not bolt-ons.
Deep & Emerging TechSlate Auto will start taking orders for its low-cost EV on June 24
A Bezos-backed “low-cost” EV taking orders with deliveries promised by year-end raises the bar on both price and speed for incumbents still fighting supply chain drag. If you’re in auto or adjacent infra, model scenarios where EV ASPs compress faster than expected — your margin story has to come from software, services, or manufacturing efficiency, not sticker price.
Deep & Emerging TechIBM plans to invest more than $10B in quantum computing over five years as it aims to build the first large-scale, error-free quantum computer by 2029 (Reuters)
$10B over five years with a 2029 target for an error-free large-scale system turns quantum from science project to dated milestone on your roadmap. If you’re in finance, pharma, logistics, or materials, you now have a concrete horizon to start modeling “post-classical” risk and optionality into long-lived systems and IP bets.